Zonisamide in children and young adults with refractory epilepsy: An open label, multicenter Italian study

Salvatore Mangano, Pietro Parisi, Giuseppe Coppola, Pasquale Parisi, Francesca Felicia Operto, Anna Luchetti, Antonio Pascotto, Emilio Franzoni, Paolo Curatolo, Paola Iannetti, Salvatore Grosso, Andrea Pelliccia, Paolo Balestri, Giangennaro Coppola, Alberto Verrotti

Risultato della ricerca: Articlepeer review

27 Citazioni (Scopus)


PURPOSE: To report on the first multicenter Italian experience with zonisamide as an add-on drug for refractory generalised or partial epilepsy in children, adolescents and young adults. METHODS: The patients were enrolled in a prospective, add-on, open-label treatment study from eight Italian centres for children and adolescent epilepsy care. Eighty-two young patients (45 males, 37 females), aged between 3 and 34 years (mean 13.1 years), all affected by partial (47) or generalised (35) refractory epilepsy, were enrolled in the study. ZNS was added to the baseline therapy at a starting dose of 1 mg/kg/day twice daily. This dose was increased by 2 mg/kg every 1-2 weeks over a period of up 3 months, according to the patient's response and tolerability, up to a maximum dose of 12 mg/kg. ZNS was given at the mean daily dose of 5.7/mg/kg/24 h (range 1-12 mg/kg). RESULTS: After a mean follow-up period of 11.9 months (range 2-64 months), 9 patients (10.9%) were seizure-free. The number of seizures decreased by 50-99% in 31 cases (37.8%), by 25-49% in 5 cases (6.1%), remained the same in 29 cases (35.4%) and increased in 8 cases (9.7%). After 15 months of follow-up, 61 patients (74.4%) were still taking ZNS, while the remaining 21 (25.6%) had stopped. Twenty-two patients (26.8%) reported adverse effects while taking ZNS. They generally appeared during the first weeks of treatment, and were mild to moderate. The most frequent adverse effects were irritability and a reduced appetite. CONCLUSION: ZNS effectively reduced seizure frequency in this pediatric population with both partial and generalised crypto/symptomatic refractory epilepsy. Its overall tolerability was good.
Lingua originaleEnglish
pagine (da-a)112-116
Numero di pagine5
RivistaEpilepsy Research
Stato di pubblicazionePublished - 2009

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2800.2808???
  • ???subjectarea.asjc.2700.2728???


Entra nei temi di ricerca di 'Zonisamide in children and young adults with refractory epilepsy: An open label, multicenter Italian study'. Insieme formano una fingerprint unica.

Cita questo